Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Abpro Holdings Inc (ABPWW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: ABPWW (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -91.07% | Avg. Invested days 22 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta -0.39 | 52 Weeks Range 0.01 - 0.18 | Updated Date 05/24/2025 |
52 Weeks Range 0.01 - 0.18 | Updated Date 05/24/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1055.19% |
Management Effectiveness
Return on Assets (TTM) -33.51% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 3717658 |
Shares Outstanding - | Shares Floating 3717658 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Abpro Holdings Inc
Company Overview
History and Background
Abpro Holdings Inc. is a biotechnology company focused on developing next-generation antibody therapies for cancer and other diseases. Founded in 2007, they have focused on T-cell engagers and B-cell targeting.
Core Business Areas
- Therapeutic Antibody Development: Abpro focuses on developing novel antibody therapeutics, including bispecific antibodies and immunotherapies.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of their drug candidates.
- Platform Technology: Development and application of proprietary antibody discovery and engineering platforms.
Leadership and Structure
Ian Chan is the CEO. The company operates with a team focused on research and development, clinical operations, and business development.
Top Products and Market Share
Key Offerings
- ABP-300: A bispecific antibody targeting EGFR and HER3 for cancer treatment. It is currently in clinical trials. The company's competitors include companies making similar therapeutic antibodies like Amgen (AMGN) and Roche (RHHBY).
- ABP-201: An anti-VEGF antibody being developed for ophthalmic indications. Competitors include Regeneron (REGN) and Novartis (NVS).
Market Dynamics
Industry Overview
The biotechnology industry is characterized by intense competition, high research and development costs, and lengthy regulatory approval processes. There is a high demand for effective cancer therapies.
Positioning
Abpro is a clinical-stage company trying to carve out a niche in cancer therapy and other unmet medical needs, developing novel antibody technologies.
Total Addressable Market (TAM)
The global oncology drug market is expected to reach hundreds of billions of dollars. Abpro's addressable market depends on successful clinical trials and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Proprietary antibody technology platforms
- Focus on unmet medical needs
- Experienced management team
Weaknesses
- Limited financial resources
- Dependence on clinical trial outcomes
- Small company status compared to large pharmaceutical companies
Opportunities
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Expansion into new therapeutic areas
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Economic downturn impacting funding
Competitors and Market Share
Key Competitors
- AMGN
- RHHBY
- REGN
- NVS
Competitive Landscape
Abpro faces competition from large pharmaceutical companies with greater resources. They must demonstrate superior efficacy or safety to gain market share.
Growth Trajectory and Initiatives
Historical Growth: Growth is dependent on clinical trial success and subsequent commercialization.
Future Projections: Future growth is projected based on successful clinical trials and regulatory approvals of key drug candidates.
Recent Initiatives: Focus on advancing clinical trials for ABP-300 and ABP-201 and explore partnerships.
Summary
Abpro is a clinical-stage biopharmaceutical company with promising antibody technology. Success hinges on clinical trial outcomes and strategic partnerships. Risks include competition from larger companies and regulatory hurdles. Recent initiatives involve advancing key clinical trials and exploring collaborations.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a financial professional. Market share estimates are based on available data and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Abpro Holdings Inc
Exchange NASDAQ | Headquaters Woburn, MA, United States | ||
IPO Launch date 2022-03-07 | CEO & Chairman of the Board Mr. Jin Wook Suk | ||
Sector Healthcare | Industry Biotechnology | Full time employees 6 | Website https://abpro.co |
Full time employees 6 | Website https://abpro.co | ||
Abpro Holdings, Inc., a biotechnology company, focuses on novel antibody constructs for immuno-oncology and ophthalmology. Its platforms include DiversImmune, a discovery platform that generates a diverse collection of proprietary antibodies against clinically validated and novel targets; and MultiMab, an engineering platform that provides the flexibility to combine antibody building blocks in different combinations and orientations to create fit for purpose novel full-length multi-specific antibody constructs. The company's lead product candidates include ABP-102, a next generation immuno-oncology TetraBi antibody targeting HER2 and CD3 is developed for the treatment of HER2+ solid tumors, including breast and gastric cancers; and ABP-201, a TetraBi antibody format that simultaneously inhibit VEGF and ANG-2 for the treatment of vascular diseases of the eye, including diabetic macular edema and wet age-related macular degeneration. It also develops ABP-110, a TetraBi antibody targeting GPC3 and CD3 for the treatment of hepatocellular carcinoma; and ABP-150, a TetraBi antibody targeting claudin 18.2 and CD3 for the treatment of gastric cancers. The company has strategic partnership with Celltrion Inc. and Abpro Bio International, Inc. Abpro Holdings, Inc. was incorporated in 2004 and is headquartered in Woburn, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.